New drug cocktail aims to fight stomach cancer in the abdomen

NCT ID NCT05802056

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 5 times

Summary

This early-phase trial tests whether adding an immune-boosting drug (aldesleukin) to standard chemotherapy and another immunotherapy (nivolumab) can help control stomach cancer that has spread to the lining of the abdomen. About 15 adults with this advanced cancer will receive the combination. The main goals are to check safety and see if the cancer shrinks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nivolumab and aldesleukin (a lab-made immune protein)
What this could lead to
If this works, it could point toward a new treatment option for stomach cancer that has spread to the abdomen lining.
What could go wrong
This is a very early, small phase 1 trial with only 15 people. It is designed mainly to check safety, not yet to prove if the combination works. Side effects from the immune-boosting drugs can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV GASTRIC CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.